Enorama Pharma AB (publ) (STO:ERMA)

Enorama Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-65.27	-75.14	-43.81	-44.61	-42.03	-27.74
Depreciation & Amortization	0.08	0.13	0.44	0.68	0.67	0.66
Other Amortization	0.34	0.34	2.87	2.87	2.87	0.72
Asset Writedown & Restructuring Costs	-	-	17.1	-	-	-
Other Operating Activities	18.93	16.57	-	-	-	-
Change in Accounts Receivable	13.48	-1.41	0.72	2.26	4.2	-2.6
Change in Inventory	-10.58	-6.12	-6.98	-1.46	-1.6	0.48
Change in Other Net Operating Assets	-2.24	6.36	-6.04	-1.09	2.94	-1.68
Operating Cash Flow	-45.27	-59.26	-35.7	-41.35	-32.96	-30.16
Capital Expenditures	-	-	-	-	-	-0.06
Sale (Purchase) of Intangibles	-	-	-	-	-	-1.76
Investing Cash Flow	-	-	-	-	-	-1.82
Long-Term Debt Issued	-	20.13	-	2.2	20	8
Long-Term Debt Repaid	-	-	-0.44	-3.46	-2.09	-9.92
Net Debt Issued (Repaid)	36.18	20.13	-0.44	-1.26	17.91	-1.92
Issuance of Common Stock	18.49	31.17	40.4	43.13	9	43.21
Other Financing Activities	-0.02	-0.61	-4.68	-	-1.57	-1.79
Financing Cash Flow	54.65	50.69	35.29	41.86	25.35	39.51
Foreign Exchange Rate Adjustments	3.73	9.52	-3.65	1.5	-0.45	-0.06
Net Cash Flow	13.11	0.95	-4.07	2.01	-8.06	7.47
Free Cash Flow	-45.27	-59.26	-35.7	-41.35	-32.96	-30.22
Free Cash Flow Margin	-1173.88%	-2163.60%	-226.42%	-3044.85%	-481.35%	-236.14%
Free Cash Flow Per Share	-	-0.85	-0.67	-1.49	-4.21	-4.88
Cash Interest Paid	11.42	11.42	2.99	3.59	2.09	0.8
Levered Free Cash Flow	-7.02	-7.35	-34.96	-23.22	-19.52	-27.22
Unlevered Free Cash Flow	-7.02	-6.62	-34.69	-22.67	-18.72	-26.72
Change in Working Capital	0.67	-1.16	-12.31	-0.28	5.54	-3.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.